Drug
Gliolan
Gliolan is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
17%
Ph not_applicable
1
17%
Ph phase_1
3
50%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 21 (20.0%)
N/A1 (20.0%)
Trials by Status
withdrawn117%
completed467%
recruiting117%
Recent Activity
1 active trials
Showing 5 of 6
completednot_applicable
INtraoperative photoDYnamic Therapy of GliOblastoma
NCT03048240
completedphase_2
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
NCT04391062
recruitingphase_1
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
NCT05590689
withdrawnphase_1
PDT Plus Vitamin D3 for Anal Dysplasia
NCT02698293
completed
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
NCT02632370
Clinical Trials (6)
Showing 6 of 6 trials
NCT03048240Not Applicable
INtraoperative photoDYnamic Therapy of GliOblastoma
NCT04391062Phase 2
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
NCT05590689Phase 1
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
NCT02698293Phase 1
PDT Plus Vitamin D3 for Anal Dysplasia
NCT02632370
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
NCT02755142Phase 1
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6